AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16394080 — intervention group
Group type: EXPERIMENTAL
Intervention: HET group (heterozygous for GHRHR mutation)
Number of subjects: 60
Study 16394080 — intervention group
Group type: COMPARATOR
Intervention: CO group (homozygous for wild-type allele)
Number of subjects: 60
Study 16394080 — intervention group
Group type: EXPERIMENTAL
Intervention: GHD group
Number of subjects: 60
Study 16394080 — intervention group
Group type: EXPERIMENTAL
Intervention: HET group
Number of subjects: 60
Study 16394080 — intervention group
Group type: COMPARATOR
Intervention: CO group
Number of subjects: 60
Study 16400382 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiotherapy (RTx) in addition to standard therapy
Number of subjects: 273
Study 16400382 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (thyroidectomy, ablative radioiodine therapy, and diagnostic 131I whole-body scintigraphy)
Number of subjects: 273
Study 16449618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative hematopoietic stem cell transplantation (HSCT)
Number of subjects: 50
Study 16489696 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (66-70 Gy in 6(1/2)-7 weeks, 2 Gy per fraction a day, 5 fractions a week)
Number of subjects: 152
Study 16489696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (74.4-79.2 Gy in 6.2-7 weeks, 1.2 Gy per fraction twice a day)
Number of subjects: 152
Study 16489696 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation with concomitant boost (68.7-72 Gy in 6 weeks, 1.8 Gy per fraction a day and 1.5 Gy per fraction a day for boost)
Number of subjects: 152
Study 16489696 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (Conventional, Hyperfractionated, Accelerated)
Number of subjects: 152
Study 16522693 — intervention group
Group type: EXPERIMENTAL
Intervention: GH naive adult dwarfs with severe IGHD
Number of subjects: 22
Study 16522693 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 22
Study 16531613 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12
Number of subjects: 5522
Study 16531613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5522
Study 16531613 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 5522
Study 16551963 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 21
Study 16554525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg
Number of subjects: 727
Study 16554525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (238 patients) at a maximal daily dose of 200 mg
Number of subjects: 727
Study 16554525 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg
Number of subjects: 727
Study 16554526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (up to 400 mg per day)
Number of subjects: 565
Study 16554526 — intervention group
Group type: COMPARATOR
Intervention: Buspirone (up to 60 mg per day)
Number of subjects: 565
Study 16554527 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAT inhibitor pactimibe (100 mg per day)
Number of subjects: 408
Study 16554527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 16563165 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly pediatric evaluation and referral to appropriate care for infants with cleft lip and/or palate.
Number of subjects: 696
Study 16563165 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric evaluations every three months for intervened cases.
Number of subjects: 696
Study 16563165 — intervention group
Group type: COMPARATOR
Intervention: Non-intervened cases matched and compared to healthy controls.
Number of subjects: 696
Study 16628299 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral penicillin or oral amoxicillin (WHO standard treatment)
Number of subjects: 523
Study 16681848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux) plus intensity-modulated radiation therapy (IMRT)
Number of subjects: 30
Study 16689987 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 16689987 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 0
Study 16709929 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2a
Number of subjects: 27
Study 16714187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (30-325 mg daily + 200 mg twice daily)
Number of subjects: 2739
Study 16714187 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (30-325 mg daily)
Number of subjects: 2739
Study 16714187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 2739
Study 16756656 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric strengthening intervention
Number of subjects: 0
Study 16756656 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric strengthening intervention
Number of subjects: 0
Study 16756656 — intervention group
Group type: COMPARATOR
Intervention: Orthoses alone
Number of subjects: 0
Study 16757724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib, 50 mg per day given orally for 4 consecutive weeks followed by 2 weeks off per treatment cycle.
Number of subjects: 106
Study 16758521 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin product E1 in trial T1
Number of subjects: 44
Study 16758521 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin product E2 in trial T2
Number of subjects: 44
Study 16758521 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin product E2 in trial T2 (adjusted)
Number of subjects: 44
Study 16764734 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored educational intervention for GPs including educational outreach visits, workshops, audit and feedback.
Number of subjects: 600
Study 16764734 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no intervention towards prescription patterns in elderly, but educational intervention for antibiotics.
Number of subjects: 600
Study 16775234 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (15 to 240 mg per day) administered orally in four-week treatment cycles, once or twice daily.
Number of subjects: 84
Study 16775235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (AMN107) at various doses (50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1200 mg once daily; 400 mg and 600 mg twice daily)
Number of subjects: 119
Study 16775235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (AMN107)
Number of subjects: 119
Study 16776824 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits, workshops, audit and feedback conducted by trained GPs (Rx-PADs).
Number of subjects: 80
Study 16776824 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 80
Study 16781217 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.05 to 0.2 mg
Number of subjects: 310
Study 16781217 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 310
Study 16794899 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16831964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride, 12 mg/m2, administered monthly via intravenous infusion for 6 months followed by 3 additional treatments every 3 months
Number of subjects: 5
Study 16836672 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidant VITALITY 2 family ICD with Rhythm ID
Number of subjects: 2000
Study 16836672 — intervention group
Group type: COMPARATOR
Intervention: Medtronic ICD using Enhanced PR Logic or Wavelet discrimination algorithms
Number of subjects: 2000
Study 16837679 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasonography of the middle cerebral artery
Number of subjects: 165
Study 16837679 — intervention group
Group type: COMPARATOR
Intervention: Amniotic-fluid DeltaOD450
Number of subjects: 165
Study 16855264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3548
Study 16855264 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3548
Study 16855264 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 3548
Study 16855264 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-conferring genotypes in TCF7L2
Number of subjects: 3548
Study 16864722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen (measured with immunoassay)
Number of subjects: 27742
Study 16864722 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 27742
Study 16864722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen and hs-CRP combined
Number of subjects: 27742
Study 16864722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen (top quintile)
Number of subjects: 27742
Study 16864722 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP (top quintile)
Number of subjects: 27742
Study 16864730 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion
Number of subjects: 30
Study 16864730 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion after endotoxin administration
Number of subjects: 30
Study 16864730 — intervention group
Group type: EXPERIMENTAL
Intervention: K-channel blocker tetraethylammonium (TEA)
Number of subjects: 30
Study 16864730 — intervention group
Group type: EXPERIMENTAL
Intervention: NO synthase inhibitor N(G)-monomethyl-l-arginine (L-NMMA)
Number of subjects: 30
Study 16875985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (1000 mg twice a day for 6 weeks)
Number of subjects: 565
Study 16875985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565
Study 16880310 — intervention group
Group type: EXPERIMENTAL
Intervention: No touch approach to diagnostic hysteroscopy without anesthesia
Number of subjects: 130
Study 16880310 — intervention group
Group type: COMPARATOR
Intervention: Traditional diagnostic hysteroscopy with 10 mL of 3% mepivacaine hydrochloride
Number of subjects: 130
Study 16880313 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 15733
Study 16880313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15733
Study 16880313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual activity in the past year (not married or living as married)
Number of subjects: 15733
Study 16882711 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aza-2'-deoxycytidine (decitabine) 15 mg/m² IV daily for 10 days + valproic acid (VPA) escalating doses orally for 10 days (maximum 50 mg/kg daily)
Number of subjects: 54
Study 16885550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 49
Study 16899778 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (1 to 2 mg per kilogram of body weight per day subcutaneously)
Number of subjects: 18
Study 16899778 — intervention group
Group type: COMPARATOR
Intervention: Anakinra withdrawal
Number of subjects: 18
Study 16901335 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (INH, Exubera)
Number of subjects: 700
Study 16901335 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (s.c.) insulin and other licensed therapies
Number of subjects: 700
Study 16905786 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir-ritonavir alone
Number of subjects: 36
Study 16921041 — intervention group
Group type: EXPERIMENTAL
Intervention: mutKIT in inv(16) AML
Number of subjects: 110
Study 16921041 — intervention group
Group type: EXPERIMENTAL
Intervention: mutKIT in t(8;21) AML
Number of subjects: 110
Study 16925569 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose rituximab
Number of subjects: 49
Study 16943394 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 83
Study 16943394 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 83
Study 16943394 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg once daily
Number of subjects: 83
Study 16943394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 16943394 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined doses of celecoxib (200 mg twice daily and 400 mg twice daily from APC, and 400 mg once daily from PreSAP)
Number of subjects: 83
Study 16952304 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCR4 monoclonal antibody (mAb)
Number of subjects: 0
Study 16959033 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (up to 32 mg/day during 6 months)
Number of subjects: 0
Study 16959033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16962882 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dapoxetine
Number of subjects: 2614
Study 16962882 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg dapoxetine
Number of subjects: 2614
Study 16962882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2614
Study 17005949 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet transplantation using the Edmonton protocol
Number of subjects: 36
Study 17010801 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholamban R14 deletion mutation
Number of subjects: 260
Study 17010801 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical PLN mutation
Number of subjects: 260
Study 17010801 — intervention group
Group type: EXPERIMENTAL
Intervention: PLN mutations
Number of subjects: 260
Study 17012043 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted craniospinal radiotherapy followed by four cycles of cyclophosphamide-based, dose-intensive chemotherapy
Number of subjects: 134
Study 17018123 — intervention group
Group type: EXPERIMENTAL
Intervention: Campath-1H (alemtuzumab) induction with sirolimus immunosuppression
Number of subjects: 29
Study 17018123 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free immunosuppressive regimens
Number of subjects: 29
Study 17018123 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy for immunosuppression (12 on sirolimus)
Number of subjects: 29
Study 17018123 — intervention group
Group type: EXPERIMENTAL
Intervention: Campath-1H induction
Number of subjects: 29
Study 17018123 — intervention group
Group type: EXPERIMENTAL
Intervention: Campath-1H and sirolimus therapy
Number of subjects: 29
Study 17021321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg for 21 days every 4 weeks or daily)
Number of subjects: 148
Study 17060336 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (co-trimoxazole) for seven days
Number of subjects: 84
Study 17060336 — intervention group
Group type: COMPARATOR
Intervention: Placebo for seven days
Number of subjects: 84
Study 17060336 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (co-trimoxazole)
Number of subjects: 84
Study 17060336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 17060377 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2022
Study 17060377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2022
Study 17060544 — intervention group
Group type: EXPERIMENTAL
Intervention: External jugular vein (EJV) examination
Number of subjects: 35
Study 17060544 — intervention group
Group type: COMPARATOR
Intervention: Internal jugular vein (control)
Number of subjects: 35
Study 17070980 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated feedback on CPR
Number of subjects: 284
Study 17070980 — intervention group
Group type: COMPARATOR
Intervention: No feedback on CPR
Number of subjects: 284
Study 17076974 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 3.9 g daily
Number of subjects: 1530
Study 17076974 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1950-4000 mg/day
Number of subjects: 1530
Study 17076974 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen treatment
Number of subjects: 1530
Study 17079762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment (scaling and root planing before 21 weeks of gestation) with monthly tooth polishing and oral hygiene instruction
Number of subjects: 823
Study 17079762 — intervention group
Group type: COMPARATOR
Intervention: Control group (scaling and root planing after delivery)
Number of subjects: 823
Study 17079762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Number of subjects: 823
Study 17090650 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (7vPCV), administered in 3 consecutive doses in monthly intervals starting 6 to 9 months after alloHSCT
Number of subjects: 53
Study 17107609 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine and Valproate (BPN/VPA)
Number of subjects: 62
Study 17107609 — intervention group
Group type: COMPARATOR
Intervention: Clonidine and Carbamazepine (CLN/CBZ)
Number of subjects: 62
Study 17109179 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide excision as initial therapy
Number of subjects: 12
Study 17109179 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide excision as salvage therapy
Number of subjects: 12
Study 17109179 — intervention group
Group type: EXPERIMENTAL
Intervention: No neoadjuvant or adjuvant therapy
Number of subjects: 12
Study 17113426 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (60 mg or 90 mg daily)
Number of subjects: 34701
Study 17113426 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (150 mg daily)
Number of subjects: 34701
Study 17113426 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 34701
Study 17113426 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 34701
Study 17116834 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod treatment (self-applied cream or suppositories, 3 times a week for 16 weeks)
Number of subjects: 28
Study 17116834 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod treatment
Number of subjects: 28
Study 17130304 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-Monomethyl-l-arginine (250 microg/kg per minute IV) during autonomic blockade
Number of subjects: 33
Study 17130304 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-Monomethyl-l-arginine (250 microg/kg per minute IV) in intact subjects
Number of subjects: 33
Study 17130304 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective eNO blockade in normotensive smokers
Number of subjects: 33
Study 17130304 — intervention group
Group type: COMPARATOR
Intervention: Selective eNO blockade in normotensive individuals
Number of subjects: 33
Study 17133154 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (10 mg/kg twice a day for 10 days)
Number of subjects: 204
Study 17161253 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Cholesterol (TC)
Number of subjects: 15632
Study 17161253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Density Lipoprotein Cholesterol (LDL-C)
Number of subjects: 15632
Study 17161253 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Density Lipoprotein Cholesterol (HDL-C)
Number of subjects: 15632
Study 17161253 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-High-Density Lipoprotein Cholesterol (non-HDL-C)
Number of subjects: 15632
Study 17161253 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Sensitivity C-Reactive Protein (hs-CRP)
Number of subjects: 15632
Study 17161253 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Cholesterol to High-Density Lipoprotein Cholesterol (TC to HDL-C) ratio
Number of subjects: 15632
Study 17164793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncoretroviral-mediated ex vivo gene transfer in FA-A cells
Number of subjects: 2
Study 17164793 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-infusion of gene-corrected products
Number of subjects: 2
Study 17164793 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell collection
Number of subjects: 2
Study 17167135 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Number of subjects: 47
Study 17167135 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 47
Study 17174643 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 5791
Study 17174643 — intervention group
Group type: EXPERIMENTAL
Intervention: Other evidence-based beta blockers
Number of subjects: 5791
Study 17183730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (182 mg for rapid-acetylators, 83 mg for slow-acetylators) and magnesium valproate (30 mg/kg) added to neoadjuvant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) every 21 days.
Number of subjects: 16
Study 17227587 — intervention group
Group type: EXPERIMENTAL
Intervention: StO2 measurement using NIRS in group A (without severe sepsis/septic shock)
Number of subjects: 65
Study 17227587 — intervention group
Group type: EXPERIMENTAL
Intervention: StO2 measurement using NIRS in group B (with severe sepsis/septic shock)
Number of subjects: 65
Study 17227587 — intervention group
Group type: EXPERIMENTAL
Intervention: StO2 measurement in group A
Number of subjects: 65
Study 17227587 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in StO2 in group A
Number of subjects: 65
Study 17227587 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma lactate concentrations in group A
Number of subjects: 65
Study 17233910 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow derived mononuclear cell therapy
Number of subjects: 300
Study 17233910 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline with 5% autologous serum)
Number of subjects: 300
Study 17241734 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual defibrillation
Number of subjects: 1165
Study 17241734 — intervention group
Group type: COMPARATOR
Intervention: Semi-automatic defibrillation (AED)
Number of subjects: 1165
Study 17242628 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (up to 1.8 mg/kg/day)
Number of subjects: 0
Study 17251666 — intervention group
Group type: EXPERIMENTAL
Intervention: TACT protocol using bone marrow-mononuclear cells (MNCs) and peripheral blood-MNCs
Number of subjects: 7
Study 17251666 — intervention group
Group type: EXPERIMENTAL
Intervention: TACT protocol
Number of subjects: 7